Serotonin–norepinephrine reuptake inhibitor
Serotonin–Norepinephrine Reuptake Inhibitor
The Serotonin–Norepinephrine Reuptake Inhibitor (SNRI) is a class of antidepressant drugs that treat major depressive disorder, anxiety disorders, obsessive-compulsive disorder (OCD), social phobia, attention-deficit hyperactivity disorder (ADHD), chronic neuropathic pain, fibromyalgia syndrome (FMS), and menopausal symptoms. SNRIs work by increasing the levels of serotonin and norepinephrine in the brain by inhibiting their reuptake into cells.
Etymology[edit]
The term "Serotonin–Norepinephrine Reuptake Inhibitor" is derived from the drug's mechanism of action. It inhibits the reuptake of the neurotransmitters serotonin and norepinephrine, thereby increasing their levels in the brain.
History[edit]
The first SNRI, venlafaxine, was introduced by Wyeth in 1993. The FDA approved it for the treatment of depression, and later for anxiety disorders and certain types of pain. Following venlafaxine, the next SNRI to be approved was duloxetine (Cymbalta) by Eli Lilly in 2004. Duloxetine was approved for the treatment of major depression and neuropathic pain.
Mechanism of Action[edit]
SNRIs work by inhibiting the reuptake of the neurotransmitters serotonin and norepinephrine. This results in an increase in the extracellular concentrations of these neurotransmitters and therefore an increase in neurotransmission.
Related Terms[edit]
- Selective serotonin reuptake inhibitors (SSRIs)
- Norepinephrine-dopamine reuptake inhibitors (NDRIs)
- Tricyclic antidepressants (TCAs)
- Monoamine oxidase inhibitors (MAOIs)
See Also[edit]
|
|
|
-
Duloxetine
-
Serotonin–norepinephrine reuptake inhibitor
-
Desvenlafaxine
-
Duloxetine
-
Levomilnacipran
-
Milnacipran
-
Sibutramine
-
Tramadol
-
Venlafaxine
-
Serotonin–norepinephrine reuptake inhibitor
-
Serotonin–norepinephrine reuptake inhibitor
-
Serotonin–norepinephrine reuptake inhibitor
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Get started with evidence based, physician-supervised
affordable GLP-1 weight loss injections
Now available in New York City and Philadelphia:
- Semaglutide starting from $59.99/week and up
- Tirzepatide starting from $69.99/week and up (dose dependent)
✔ Evidence-based medical weight loss ✔ Insurance-friendly visits available ✔ Same-week appointments, evenings & weekends
Learn more:
Start your transformation today with W8MD weight loss centers.
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian


